Table 108Evidence profile comparing dithranol (short contact) plus coal tar vs dithranol

Quality assessmentNo of patientsEffectQuality
No of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsDithranol + Coal Tar + BBUVBDithranolRelative (95% CI)Absolute
Clearance (follow-up 3 weeks)
1
Paramsothy 1988
randomised trialsvery seriousano serious inconsistencyno serious indirectnessseriousbnone20/27 (74.1%)16/26 (61.5%)RR 1.2 (0.83 to 1.75)123 more per 1000 (from 105 fewer to 462 more)⊕○○○
VERY LOW
Mean number of days to clearance (follow-up 3 weeks; Better indicated by lower values)
1
Paramsothy 1988
randomised trialsvery seriousano serious inconsistencyno serious indirectnessno serious imprecisionnone2726-MD 0.8 higher (0.37 lower to 1.97 higher)⊕⊕○○
LOW
Mean number of weeks to relapse among clearers (follow-up unclear ; Better indicated by higher values)
1
Paramsothy 1988
randomised trialsvery seriousano serious inconsistencyno serious indirectnessno serious imprecisionnone2016-MD 8.3 higher
Combination: 18.9
Dithranol alone: 10.6
⊕⊕○○
LOW
Relapse rate (post-treatment) (follow-up unclear time post-treatment)
1
Paramsothy 1988
randomised trialsvery seriousano serious inconsistencyno serious indirectnessvery seriouscnone14/20 (70%)13/16 (81.3%)RR 0.86 (0.59 to 1.25)114 fewer per 1000 (from 333 fewer to 203 more)⊕○○○
VERY LOW
a

Unclear method of randomisation, no allocation concealment, unblinded

b

Confidence interval ranges from clinically important effect to no effect

c

Confidence interval crosses the boundary for clinical significance in favour of both interventions, as well as line of no effect

From: 9, Phototherapy

Cover of Psoriasis
Psoriasis: Assessment and Management of Psoriasis.
NICE Clinical Guidelines, No. 153.
National Clinical Guideline Centre (UK).
Copyright © National Clinical Guideline Centre - October 2012.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.